Yassel Hernandez

Passionate Nurse with experience in diverse healthcare settings and clinical research units. Competent in care plan development and implementation, patient care coordination and interdisciplinary teams collaboration. Bilingual nurse with talents in preventive care and injury evaluation. Possessing a positive, outgoing attitude, and dynamic active listening skills. Noted for creating successful employee health programs and able to learn new concepts quickly. Multi-talented clinical research professional proficient in handling patient information, laboratory samples and compliance procedures for different clinical trials. Well-organized and hardworking with excellent communication and planning skills.

· A Single-Center, Randomized, Open-Label, Single-Dose, Four-Way Crossover Study Comparing The Oral Bioavailability Of XXX From Solid Dosage Formulations To The Dry Powder Suspension Formulation In Fasted, Healthy Volunteers.

· A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety and Tolerability Study of XXX after Oral Administration to Healthy Subjects.

· The Relative Bioavailability Of Two XXX® 7-Day Estradiol Transdermal Systems (ETS) To Twice Weekly XXX® (ETS).

· An Open, Randomized, Two-Part, 3-Period Crossover Study To Investigate The Potential For Drug Interactions Between XXX And XXX And XXX And XXX In Healthy Subjects.

· Single-Dose Pharmacokinetics And Safety Of 10 mg XXX In Subjects With Hepatic Impairment Compared To Healthy Adult Subjects.

· An Open-Label, Randomized, Four-Period, Crossover Study to Estimate the Effect of Formulation on The Relative Bioavailability of Single Dose Oral 200-mg XXX in Healthy Postmenopausal Women.

· Single-Dose Pharmacokinetics And Safety Of Enteric-Coated XXX In Subjects With Hepatic Impairment Compared To Healthy Adult Subjects.

· A Randomized, Double-Blind, Placebo Controlled, PK/PD Modeling, Multicenter Study to Compare The Β1-Blocking Effects of XXX Immediate Release Tablets at Steady State in Adult Patients with Essential Hypertension, By Evaluating Heart Rate Response to Bicycle Ergometry

· A Prospective, Double-Blinded, Multi-Center Pivotal Trial of Autologous Adult Adipose-Derived Regenerative Cell Injection into Chronic Partial-Thickness Rotator Cuff Tears.

· A Longitudinal, Multi-Center Safety Study of Autologous Adult Adipose-Derived Regenerative Cell Injection into Chronic Partial-Thickness Rotator Cuff Tears

· A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older

· A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the XXX Stimulator Vericiguat/XXX in Adults With Chronic Heart Failure With Reduced Ejection Fraction

· An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of XXX Sustained-Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder

· A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of XXX Sustained-release Tablets in Adults with Attention-deficit/Hyperactivity Disorder

· A PPD_NIH/NIAD_Symptomatic non-hospitalized COVID_ACTIV-2/A5401

· An Open-Label, Pilot Pharmacokinetic Study of XXX Phosphate Cream in Pediatric Subjects with Atopic Dermatitis

· A phase 2, multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of XXX in subjects with moderate to severe atopic dermatitis

· A Phase 3 Efficacy and Safety Study of XXX for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

· Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX Cream, 1% in Pediatric Subjects with Extensive Atopic Dermatitis

· A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral XXX for moderate to severe pruritus in adult subjects with atopic dermatitis

· An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of XXX Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis

· A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of XXX Cream 0.3% in Plaque Psoriasis

· A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.15% Administered QD in Subjects with Atopic Dermatitis

· A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.05% Administered QD in Subjects with Atopic Dermatitis

· A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.05%and XXX Cream 0.15% Administered QD in Adolescent and Adult Subjects with Atopic Dermatitis

· A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of XXX Cream 0.15% and XXX Cream 0.05% in Subjects with Atopic Dermatitis

· A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability of Once Daily XXX Capsules in Children and Adolescents with Attention-deficit/Hyperactivity Disorder

· A Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of XXX of Cream 1% in Subjects with Atopic Dermatitis

· A 52-week, randomized, double-blind, double-dummy, parallel group, multi-center, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with XXX compared with mepolizumab or benralizumab

· A 52-week, randomized, double-blind, placebo-controlled, parallel group, multi-center study of the efficacy and safety of XXX adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype.

· Randomized, double-blind, placebo-controlled, parallel group Phase 3 study to evaluate the efficacy, safety, and tolerability of XXX in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

· A Randomized, Multicenter, Double-Blind, 4-Arm, Parallel-Group, Active-Controlled, Phase 3 Study to Compare Efficacy, Safety and Immunogenicity of XXX Administered Through Subcutaneous Route Every 4 Weeks in Patients with Chronic Idiopathic Urticaria (CIU) who Remained Symptomatic Despite Treatment with Approved Doses of H1 Antihistamines

· A double-blind placebo-controlled study to assess the efficacy and safety of oral XXX versus placebo in patients with mild to moderate COVID-19 disease.